Drug Trial Radar · NCT07766317
Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jun 2030
Study completion Jun 2032
Sponsor
- Lead sponsor
- Gritbio Medicine, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single-arm phase 1/2 clinical trial to evaluate the safety and tolerability of GT201 as a monotherapy or in combination with anti-PD-1 therapy in patients with advanced solid tumors, and to evaluate the efficacy of this therapy.
Conditions
- Advanced Solid Tumors Cancer
Interventions
GT201Biological
A tumor sample from individual participant is collected through a surgical resection for ex vivo manufacturing of GT201 TIL cell product.
IL-2 and PD-1Biological
Participants tandemly receives a lymphodepleting regimen, GT201 TIL product, and IL-2. Some participants may also receive a PD-1 inhibitor following GT201 infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety of GT201 in the treatment of recurrent or metastatic solid tumorsTime frame: Upto 2 years
- To assess the safety of GT201 in the treatment of recurrent or metastatic solid tumorsTime frame: Upto 2 years
- To assess the tolerance of GT201 and decide on the recommended Phase 2 dose.Time frame: Upto 2 years
- To assess the Objective Response Rate (ORR) of GT201 infusion in accordance with RECIST v1.1Time frame: Upto 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.